Hugo A Katus

Author PubWeight™ 3.07^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.	Eur Heart J	2015	0.80
2	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.	Heart	2016	0.79
3	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.	Am Heart J	2016	0.78
4	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.	Eur Heart J	2014	0.76
5	No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.	Int J Cardiol	2014	0.75
6	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.	J Thromb Thrombolysis	2017	0.75
7	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.	Eur Heart J Acute Cardiovasc Care	2022	0.75
8	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.	Am Heart J	2017	0.75